曲罗芦单抗治疗中重度特应性皮炎的研究进展

Research progress of tralokinumab for the treatment of moderate and severe atopic dermatitis

扫码查看

原文链接

NETL
NSTL
万方数据

中文摘要：曲罗芦单抗(tralokinumab)是由丹麦利奥制药有限公司(LEO pharma)研发的一种白细胞介素13选择性抑制剂,于2021年12月27日被美国食品药品监督管理局批准用于治疗18岁或以上、疾病无法通过局部处方疗法充分控制或治疗的中重度特应性皮炎成人患者.本文对曲罗芦单抗治疗中重度特应性皮炎的研究进展作一综述.

外文摘要：Tralokinumab is a selective interleukin-13 inhibitor developed by LEO Pharma in Denmark.It was granted approval by the US Food and Drug Administration on December 27,2021,for the treatment of patients aged 18 years or older with moderate to severe atopic dermatitis whose disease is refractory to or cannot be fully controlled by local prescription therapy.This article presents a comprehensive review of the recent research progress in the treatment of moderate to severe atopic dermatitis with tralokinumab.

外文关键词：

Dermatitis,atopicChemistry,pharmaceuticalClinical studyPharmacokineticsAbsorption,physicochemicalBiotransformationDrug-related side effects and adverse reactionsDrug evaluation,preclinicalTralokinumab

作者：

张金桂、王超

展开 >

作者单位：

海南省人民医院Ⅰ期临床试验病房,海口 570311

琼海市人民医院药学部,琼海 571400

关键词：

皮炎,特应性化学,药物临床研究药代动力学吸收,理化生物转化药物相关性副作用和不良反应药物评价,临床前曲罗芦单抗

出版年：

2024

DOI：

10.3760/cma.j.cn341190-20220118-00046